Novartis Pharmaceuticals Corporation Human Prescription Drug
NDC Database
Novartis Pharmaceuticals Corporation Human Prescription Drug
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 49
- Latest Marketing Date 2024-03-14
- Data Source FDA
- First Marketing Date 1983-11-14
Company Overview
Company
Novartis Pharmaceuticals Corporation Human Prescription Drug
Country
Switzerland
Website
Social Profiles
Company Snapshot
Novartis Pharmaceuticals Corporation Human Prescription Drug
Klybeckstrasse 141, CH-4057, Basel
Switzerland
www.novartis.com/ View on MapNDC Records ( 49 records )
Nonproprietary Name
letrozole
Dosage Form
TABLET, FILM COATED
Strength
2.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LETROZOLE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
1997-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET, FOR SUSPENSION
Strength
3 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2012-08-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET, FOR SUSPENSION
Strength
5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2012-08-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
trametinib
Dosage Form
TABLET, FILM COATED
Strength
0.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAMETINIB DIMETHYL SULFOXIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2016-03-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
trametinib
Dosage Form
TABLET, FILM COATED
Strength
2 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAMETINIB DIMETHYL SULFOXIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2016-03-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
0.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-04-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
0.75 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-04-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-04-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
asciminib
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ASCIMINIB HYDROCHLORIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2021-10-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
asciminib
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ASCIMINIB HYDROCHLORIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2021-10-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-05-24
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
siponimod
Dosage Form
TABLET, FILM COATED
Strength
0.25 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIPONIMOD
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
siponimod
Dosage Form
TABLET, FILM COATED
Strength
1 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIPONIMOD
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
siponimod
Dosage Form
TABLET, FILM COATED
Strength
2 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIPONIMOD
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2022-04-05
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
125 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2022-04-05
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
dabrafenib
Dosage Form
TABLET, FOR SUSPENSION
Strength
10 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DABRAFENIB MESYLATE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2023-03-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fingolimod hcl
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FINGOLIMOD HYDROCHLORIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-09-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
nilotinib
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NILOTINIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-10-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
nilotinib
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NILOTINIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-10-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
nilotinib
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NILOTINIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-10-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET, FOR SUSPENSION
Strength
2 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2012-08-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-05-24
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
7.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2011-07-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
omalizumab
Dosage Form
INJECTION, SOLUTION
Strength
75 mg/.5mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMALIZUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2018-09-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
omalizumab
Dosage Form
INJECTION, SOLUTION
Strength
150 mg/mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMALIZUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2018-09-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
omalizumab
Dosage Form
INJECTION, SOLUTION
Strength
300 mg/2mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMALIZUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2023-08-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
2.5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-07-09
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-03-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-03-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
everolimus
Dosage Form
TABLET
Strength
0.25 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EVEROLIMUS
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2010-04-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2019-05-24
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
asciminib
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ASCIMINIB HYDROCHLORIDE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2021-10-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
alpelisib
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPELISIB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2022-04-05
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
canakinumab
Dosage Form
INJECTION, SOLUTION
Strength
150 mg/mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CANAKINUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2016-12-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
cyclosporine
Dosage Form
INJECTION
Strength
50 mg/mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
1983-11-14
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
basiliximab
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Strength
10 mg/2.5mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BASILIXIMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
1998-05-12
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
tislelizumab-jsgr
Dosage Form
INJECTION, SOLUTION, CONCENTRATE
Strength
10 mg/mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TISLELIZUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2024-03-14
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
omalizumab
Dosage Form
INJECTION, SOLUTION
Strength
150 mg/1.2mL
Labeler
Novartis Pharma Stein AG
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMALIZUMAB
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2003-06-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
amlodipine besylate and valsartan
Dosage Form
TABLET, FILM COATED
Strength
5; 160 mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
amlodipine valsartan and hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
5; 12.5; 160 mg/1; mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-04-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
amlodipine valsartan and hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
10; 25; 320 mg/1; mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-04-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
amlodipine valsartan and hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
5; 25; 160 mg/1; mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-04-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
amlodipine valsartan and hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
10; 25; 160 mg/1; mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-04-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
amlodipine besylate and valsartan
Dosage Form
TABLET, FILM COATED
Strength
5; 320 mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
amlodipine besylate and valsartan
Dosage Form
TABLET, FILM COATED
Strength
10; 320 mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Clarithromycin
Dosage Form
PELLET
Strength
400 mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLARITHROMYCIN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2007-09-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Somatropin
Dosage Form
INJECTION, SOLUTION
Strength
10 mg/1.5mL
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SOMATROPIN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2006-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
amlodipine valsartan and hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
10; 12.5; 160 mg/1; mg/1; mg/1
Labeler
Novartis Pharmaceuticals Corporation
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
HUMAN PRESCRIPTION DRUG
DEA Schedule
Start Marketing Date
2009-04-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
NDC Type Breakdown
49 total- Human Prescription Drug
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
17088-0100
Nonproprietary Name
letrozole
Labeler
Novartis Pharma Stein AG
Dosage Form
TABLET, FILM COATED
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.